MX387753B - Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario. - Google Patents

Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario.

Info

Publication number
MX387753B
MX387753B MX2016009428A MX2016009428A MX387753B MX 387753 B MX387753 B MX 387753B MX 2016009428 A MX2016009428 A MX 2016009428A MX 2016009428 A MX2016009428 A MX 2016009428A MX 387753 B MX387753 B MX 387753B
Authority
MX
Mexico
Prior art keywords
plasma kallikrein
binding proteins
hereditary angioedema
treat hereditary
treat
Prior art date
Application number
MX2016009428A
Other languages
English (en)
Other versions
MX2016009428A (es
Inventor
Burt Adelman
Christopher Tenhoor
Daniel J Sexton
Jon A Kenniston
Joseph Biedenkapp
Ryan Faucette
Ryan Iarrobino
Yung Chyung
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2016009428A publication Critical patent/MX2016009428A/es
Publication of MX387753B publication Critical patent/MX387753B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
    • C12Y207/03002—Creatine kinase (2.7.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a proteínas de unión a calicreína en plasma tales como los anticuerpos que se unen a calicreina activa en plasma y los métodos para utilizar estas proteínas para tratar el angioedema hereditario.
MX2016009428A 2014-01-21 2015-01-21 Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario. MX387753B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461929716P 2014-01-21 2014-01-21
US201461944361P 2014-02-25 2014-02-25
US201462021397P 2014-07-07 2014-07-07
PCT/US2015/012212 WO2015112578A1 (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Publications (2)

Publication Number Publication Date
MX2016009428A MX2016009428A (es) 2017-04-13
MX387753B true MX387753B (es) 2025-03-18

Family

ID=53681890

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009428A MX387753B (es) 2014-01-21 2015-01-21 Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario.
MX2021013665A MX2021013665A (es) 2014-01-21 2016-07-20 Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013665A MX2021013665A (es) 2014-01-21 2016-07-20 Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.

Country Status (18)

Country Link
US (2) US11084884B2 (es)
EP (2) EP3848057B1 (es)
JP (4) JP6845012B2 (es)
KR (3) KR102424183B1 (es)
CN (2) CN116585468A (es)
AU (3) AU2015209481C1 (es)
BR (1) BR112016016916B1 (es)
CA (1) CA2937329C (es)
DK (1) DK3096798T3 (es)
EA (1) EA038532B1 (es)
ES (1) ES2856076T3 (es)
IL (3) IL246864B (es)
MX (2) MX387753B (es)
NZ (2) NZ723369A (es)
PL (1) PL3096798T3 (es)
PT (1) PT3096798T (es)
WO (1) WO2015112578A1 (es)
ZA (2) ZA201605342B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011917A1 (en) 2010-01-06 2022-06-15 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
IL273688B2 (en) 2013-01-20 2024-12-01 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
EP3594244A1 (en) 2013-03-15 2020-01-15 Dyax Corp. Anti-plasma kallikrein antibodies
ES2873204T3 (es) 2013-10-21 2021-11-03 Takeda Pharmaceuticals Co Diagnóstico y tratamiento de enfermedades autoinmunes
EP3808857B1 (en) 2013-10-21 2025-12-10 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
EA038532B1 (ru) * 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
KR20230109785A (ko) 2014-03-27 2023-07-20 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
BR112017020864A2 (en) * 2015-03-30 2018-07-10 Dyax Corp. plasma kallikrein inhibitors and their uses for the prevention of hereditary angioedema attack
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
EP4354146A3 (en) * 2015-10-19 2024-06-05 Takeda Pharmaceutical Company Limited Immunoassay for the detection of cleaved high molecular weight kininogen
IL311156A (en) * 2015-12-11 2024-04-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
KR102513485B1 (ko) * 2016-09-16 2023-03-23 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커
EA201990730A1 (ru) 2016-09-16 2019-08-30 Дайэкс Корп. Рнк-биомаркеры для наследственного ангионевротического отека
BR112020007405A2 (pt) * 2017-10-18 2020-12-08 Regenxbio Inc. Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos
JP7360716B2 (ja) 2017-12-01 2023-10-13 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
HRP20250277T1 (hr) 2017-12-01 2025-05-09 Suzhou Ribo Life Science Co., Ltd. Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
EP3719126B1 (en) 2017-12-01 2025-01-01 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
CN118291456A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
EP3718572B1 (en) 2017-12-01 2024-07-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use
EP3732185B1 (en) 2017-12-29 2025-02-26 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
CN111655849B (zh) 2018-08-21 2024-05-10 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
EP3862024A4 (en) 2018-09-30 2022-08-17 Suzhou Ribo Life Science Co., Ltd. SHORT INTERFERENT RNA CONJUGATE, METHOD FOR PREPARATION AND USE THEREOF
WO2020135673A1 (zh) 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
US12163956B2 (en) 2019-02-21 2024-12-10 Takeda Pharmaceutical Company Limited Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples
JP2022525164A (ja) * 2019-03-14 2022-05-11 武田薬品工業株式会社 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用
CN113227376B (zh) 2019-05-22 2024-04-09 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
JP7614650B2 (ja) * 2019-05-24 2025-01-16 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体並びに調製方法と使用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0296171A4 (en) 1986-03-03 1989-11-07 Brigham & Womens Hospital ASSESSMENT PROCEDURE FOR NEPHROTOXICITY.
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT739355E (pt) 1994-01-11 2005-01-31 Dyax Corp Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1674480A4 (en) 2003-09-04 2007-06-20 Riken ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION
EP1713929A2 (en) 2004-02-03 2006-10-25 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
LT1854477T (lt) 2006-03-16 2016-12-12 Dyax Corp. Peptidai, slopinantys plazmos kalikreiną, skirti naudoti oftalmologinių sutrikimų gydymui
WO2008016883A2 (en) 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
KR100846354B1 (ko) 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
NZ582930A (en) * 2007-07-20 2012-11-30 Diamedica Inc Tissue kallikrein for the treatment of diseases associated with amyloid protein
AU2008288772A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2010003101A2 (en) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Il6 immunotherapeutics
EP2385843A4 (en) * 2009-01-06 2013-02-27 Dyax Corp TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
CN101928346B (zh) 2009-07-31 2013-01-16 华中科技大学同济医学院附属同济医院 一种抗人组织激肽释放酶单克隆抗体及其制备
EP4011917A1 (en) 2010-01-06 2022-06-15 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
EP2697196A1 (en) 2011-04-13 2014-02-19 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
AU2012250872B2 (en) 2011-05-02 2017-07-13 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
WO2013123114A2 (en) 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
IL273688B2 (en) 2013-01-20 2024-12-01 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
AU2014207409B2 (en) 2013-01-20 2019-12-19 Takeda Pharmaceutical Company Limited Evaluation, assays and treatment of pKal-mediated disorders
EP3594244A1 (en) 2013-03-15 2020-01-15 Dyax Corp. Anti-plasma kallikrein antibodies
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
EP3808857B1 (en) 2013-10-21 2025-12-10 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
KR20230109785A (ko) 2014-03-27 2023-07-20 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
BR112017020864A2 (en) 2015-03-30 2018-07-10 Dyax Corp. plasma kallikrein inhibitors and their uses for the prevention of hereditary angioedema attack
IL311156A (en) 2015-12-11 2024-04-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
KR20250030022A (ko) * 2016-09-16 2025-03-05 다케다 파머수티컬 컴패니 리미티드 접촉 활성화 시스템과 연관된 질환을 위한 대사물질 바이오마커
EP3678553B1 (en) 2017-09-05 2024-05-22 Sanolla Ltd Diagnosis of pathologies using infrasonic signatures
JP7585193B2 (ja) 2018-08-30 2024-11-18 武田薬品工業株式会社 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用
JP2022525164A (ja) 2019-03-14 2022-05-11 武田薬品工業株式会社 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用
JP2023510854A (ja) 2020-01-13 2023-03-15 武田薬品工業株式会社 小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用

Also Published As

Publication number Publication date
EA201691470A1 (ru) 2016-12-30
PT3096798T (pt) 2021-02-25
NZ761006A (en) 2023-04-28
BR112016016916B1 (pt) 2023-12-19
CN106132442A (zh) 2016-11-16
JP7164502B2 (ja) 2022-11-01
AU2020244370A1 (en) 2020-10-29
DK3096798T3 (da) 2021-03-01
MX2021013665A (es) 2021-12-10
WO2015112578A1 (en) 2015-07-30
US20210087293A1 (en) 2021-03-25
US20170002094A1 (en) 2017-01-05
IL278062B (en) 2022-06-01
ZA202004653B (en) 2022-01-26
KR102424183B1 (ko) 2022-07-26
KR20240049627A (ko) 2024-04-16
AU2015209481B2 (en) 2020-07-30
CA2937329A1 (en) 2015-07-30
IL263669B (en) 2020-10-29
IL278062A (en) 2020-11-30
AU2015209481C1 (en) 2020-10-29
MX2016009428A (es) 2017-04-13
EP3096798B1 (en) 2020-11-25
IL246864B (en) 2018-12-31
AU2024203436A1 (en) 2024-06-13
BR112016016916A2 (pt) 2018-01-23
AU2015209481A1 (en) 2016-08-25
JP2020002171A (ja) 2020-01-09
IL263669A (en) 2019-01-31
JP2023015087A (ja) 2023-01-31
JP2017503820A (ja) 2017-02-02
AU2020244370B2 (en) 2024-03-07
BR112016016916A8 (pt) 2018-05-02
CA2937329C (en) 2022-05-31
JP2024170495A (ja) 2024-12-10
JP6845012B2 (ja) 2021-03-17
ZA201605342B (en) 2020-11-25
EA038532B1 (ru) 2021-09-10
KR20220107077A (ko) 2022-08-01
KR20160122169A (ko) 2016-10-21
EP3848057B1 (en) 2025-12-10
EP3096798A1 (en) 2016-11-30
NZ723369A (en) 2022-12-23
US12384854B2 (en) 2025-08-12
CN116585468A (zh) 2023-08-15
US11084884B2 (en) 2021-08-10
KR20240033156A (ko) 2024-03-12
PL3096798T3 (pl) 2021-07-26
ES2856076T3 (es) 2021-09-27
CN106132442B (zh) 2023-07-14
EP3848057A1 (en) 2021-07-14
EP3096798A4 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
MX387753B (es) Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario.
PH12019502724A1 (en) Compositions for modulating c9orf72 expression
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
IL255615A (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
ZA201803661B (en) Compositions and methods for decreasing tau expression
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
IL251759B (en) Compositions and methods for treating insomnia
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
IL252418B (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
DK2914630T3 (da) Hidtil ukendte antigen-bindende proteiner og deres anvendelse som adresseringsprodukt til behandling af kræft
MX2015003701A (es) Composiciones para tratamiento.
IL272246A (en) Compositions and methods for treating galactosemia
IL257764B (en) Methods for treatment of diseases
EA201791538A1 (ru) Способ предотвращения или лечения потери слуха
MX2017005064A (es) Metodos para tratar afecciones oculares.
MX2018012230A (es) Métodos para tratar enfermedades oculares.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
HUE052098T2 (hu) Prohemosztatikus fehérjék vérzés kezelésére
IL252707A0 (en) Compositions and methods for treating diseases and conditions
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
BR112017026193A2 (pt) agentes de clarificação para bioprocessamento de adsorventes e métodos de produção e uso dos mesmos
MX380683B (es) Lisobactina para su uso en el tratamiento de la mastitis bovina.
EA202191382A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека